Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalbavancin - Durata Therapeutics

Drug Profile

Dalbavancin - Durata Therapeutics

Alternative Names: A-A-1; BI-397; Dalbavancin hydrochloride; Dalvance; MDL-63,397; V-Glycopeptide; VER 001; VGE; Xydalba; Zevan; Zeven

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cipher Pharmaceuticals; Durata Therapeutics; Pfizer
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacterial endocarditis; Osteomyelitis
  • Phase I Bacterial infections
  • No development reported Catheter infections; Diabetic foot ulcer; Gonorrhoea; Pneumonia

Most Recent Events

  • 15 Nov 2018 Cipher Pharmaceuticals plans to launch dalbavancin hydrochloride in Canada in first half of 2019
  • 04 Sep 2018 Registered for Skin and soft tissue infections in Canada (IV)
  • 13 Aug 2018 Launched for Skin and soft tissue infections (Second-line therapy or greater) in Luxembourg, Wales (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top